Fannie Mae, Freddie Mac shares tumble after conservatorship comments
SAN FRANCISCO— Doximity , Inc. (NYSE:DOCS) director Yang Watkin Phoebe L. recently sold shares of the company’s Class A common stock, according to a filing with the Securities and Exchange Commission. The transaction, dated February 12, 2025, involved the sale of 2,889 shares at an average price of $75.185 per share, totaling approximately $217,209. The sale comes as Doximity’s stock has surged 159% over the past year, with the company now commanding a market capitalization of $14.3 billion. According to InvestingPro analysis, the stock appears to be trading above its Fair Value.
Following this transaction, Yang holds 14,729 shares of Doximity stock. The sale was conducted as a direct ownership transaction. Doximity, a leading digital platform for medical professionals, continues to be a significant player in the healthcare technology sector, boasting impressive gross profit margins of 90% and maintaining a "GREAT" financial health rating. For comprehensive insider trading analysis and 18 additional key insights, visit InvestingPro.
In other recent news, Doximity has been the focus of multiple analysts’ revisions following its impressive third-quarter results. Jefferies analyst Glen Santangelo raised Doximity’s price target to $88, citing the company’s robust growth and profitability, including a growth rate exceeding 25% and an EBITDA margin above 60%. Similarly, Mizuho (NYSE:MFG) Securities analyst Steven Valiquette adjusted the price target on Doximity to $65, following the company’s revenue of $168 million, a 25% year-over-year increase, and EBITDA of $102 million, a 39% year-over-year growth.
Piper Sandler analyst Sean Wieland upgraded Doximity’s stock rating from Neutral to Overweight and significantly raised the price target to $78, acknowledging Doximity’s record prescriber engagement and promising bookings momentum. KeyBanc Capital Markets maintained its $65 price target on Doximity, highlighting the company’s top and bottom-line growth, with revenues increasing by 25% year-over-year and adjusted EBITDA margins reaching 60.5%.
Lastly, Needham maintained a Buy rating on Doximity and increased its price target to $82, noting significant upselling leading to top-line outperformance and an unprecedented adjusted EBITDA margin surpassing 60%. These recent developments underline Doximity’s strong financial performance and promising growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.